SCHEMBL30891375

O=C(CCCCCNC(=O)CN(CC(=O)NCCCCCNC(=O)OCc1ccccc1)CC(=O)NCCCC[C@@H](C(=O)NCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)N(CC(=O)NCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)CC(=O)NCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)NCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O

nearest known ligand 0.56

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SIRT2	Q8IXJ6	2/20	0.44

▸	EPOR	P19235	8/20	0.43

▸	MMP13	P45452	1/20	0.41

▸	FOLH1	Q04609	4/20	0.41

▸	PTGER4	P35408	2/20	0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30891439	0.96	SIRT2 (0.43)	SIRT2EPORMMP13FOLH1PTGER4
SCHEMBL30891404	0.96	SIRT2 (0.43)	SIRT2EPORMMP13FOLH1PTGER4
SCHEMBL30891442	0.96	SIRT2 (0.43)	SIRT2EPORMMP13FOLH1PTGER4
SCHEMBL23519413	0.94	FOLH1 (0.44)	EPORFOLH1
SCHEMBL20510932	0.94	FOLH1 (0.44)	EPORFOLH1
SCHEMBL30891474	0.93	SIRT2 (0.47)	SIRT2EPORFOLH1PTGER4
SCHEMBL23497305	0.92	EPOR (0.45)	SIRT2EPORMMP13
SCHEMBL23497306	0.92	EPOR (0.45)	SIRT2EPORMMP13
SCHEMBL30891337	0.92	SIRT2 (0.50)	SIRT2EPORPTGER4
SCHEMBL20510760	0.92	EPOR (0.44)	SIRT2EPORMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20260021190-A1	GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES	MERCK SHARP & DOHME LLC (US)	2026-01-22	—	—	US	disclosed
EP-4615487-A1	GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES	Merck Sharp & Dohme LLC (US)	2025-09-17	—	—	EP	disclosed
WO-2024102633-A1	GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES	MERCK SHARP & DOHME LLC (US)	2024-05-16	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20260021190-A1	GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES	INSR, GPR119, GLP1R	SIRT2 836/4885EPOR 88/4885MMP13 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.